Skip to content
woman holding drug container

BioNova Receives Investigational New Drug Clearance for BN104 for the Treatment of Acute Leukemia in China

BioNova today announced that Center of Drug Evaluation (CDE) had approved its investigational new drug (IND) application for BN104 for the treatment of relapsed/refractory (R/R) acute leukemia in China.

Back To Top